Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Vivos Inc. develops precision radionuclide therapy devices, primarily RadioGel, for treating non-resectable tumors in humans and animals. Its core focus includes FDA-approved cancer treatments, veterinary oncology solutions under the IsoPet brand, and innovative isotope technologies. The company leverages strategic partnerships, proprietary patents, and clinical trials to deliver targeted, minimally invasive therapies with competitive advantages in safety, efficacy, and regulatory progress.
This description was generated via AI from an annual report. Updated about 1 year ago.